Compare Repligen Corporation Common Stock (RGEN) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Xylem, Inc. — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Xylem, Inc. trades at $102.9 (market cap $23.94B). The key difference: Xylem, Inc. is far larger — about 2.1× Repligen Corporation Common Stock's market cap, and Xylem, Inc. pays a 1.68% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Xylem, Inc. for 51 Days on average.
| RGEN | XYL | |
|---|---|---|
Market Cap | $11.14B | $23.94B |
Volume | 1,259,263 | 1,097,519 |
Sector | Health | Industrials |
52-Week High | $194.57 | $152.95 |
52-Week Low | $102.87 | $100.92 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $11.02B | $25.72B |
Dividend Yield | — | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Xylem (XYL) trades at $102.74, showing modest daily gains of 0.15%. The stock demonstrates strong fundamental performance with consistent earnings beats and revenue growth from $5.5B in 2022 to $9.0B in 2025. Technical indicators signal bearish momentum despite neutral oscillators, with key support at $101. Recent developments include strategic acquisitions of Cornell Pump and Roper Pump, strengthening the company's industrial water solutions portfolio.
Xylem presents a compelling investment case with solid profitability (11.15% net margin) and analyst consensus target of $146.63 offering 43% upside potential. However, technical weakness and China market challenges pose near-term risks. The company's focus on water infrastructure and digital solutions positions it well for long-term growth in essential water technology markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
